Abbott Laboratories(us:ABT)
131.69
-0.72%
Updated on 2025-04-02
Open:132.48
Close:131.69
High:132.63
Low:131.08
Prev Close:132.65
Volume:4.23M
Turnover:557.15M
Turnover Ratio:0.24%
Shares:1.73B
MarketCap:228.39B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 114 | 6412046 | 0.37% | 4 | 40 | 50 |
| 2024-03-31 | 2892 | 1283829040 | 73.80% | 170 | 1103 | 1222 |
| 2023-12-31 | 2851 | 1300513062 | 75.00% | 292 | 933 | 1277 |
| 2023-09-30 | 2736 | 1269786443 | 73.14% | 136 | 943 | 1271 |
| 2023-06-30 | 2721 | 1274378968 | 73.43% | 143 | 1001 | 1184 |
| 2023-03-31 | 2721 | 1269092101 | 72.98% | 136 | 1001 | 1193 |
| 2022-12-31 | 2758 | 1290434878 | 74.26% | 268 | 982 | 1152 |
| 2022-09-30 | 2675 | 1272407388 | 72.98% | 91 | 1069 | 1087 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Vanguard Group Inc | 166353894 | 9.56% | 1051973 | 0.64% |
| 2024-06-30 | Blackrock Inc. | 131129688 | 7.54% | -1946540 | -1.46% |
| 2024-06-30 | State Street Corp | 74396622 | 4.28% | -342018 | -0.46% |
| 2024-06-30 | Capital International Investors | 71799826 | 4.13% | 1622262 | 2.31% |
| 2024-06-30 | Capital Research Global Investors | 57237592 | 3.29% | -26747139 | -31.85% |
| 2024-06-30 | Morgan Stanley | 35616923 | 2.05% | -395059 | -1.10% |
| 2024-06-30 | Geode Capital Management, Llc | 34414434 | 1.98% | 680719 | 2.02% |
| 2024-06-30 | Wellington Management Group Llp | 25530536 | 1.47% | -2727959 | -9.65% |
| 2024-06-30 | Northern Trust Corp | 20678352 | 1.19% | -345034 | -1.64% |
| 2024-06-30 | Norges Bank | 20356932 | 1.17% | 1134295 | 5.90% |
About
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Address:100 Abbott Park Road
Website:http://www.abbott.com
Market Movers